YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Synthesis of New Benzylpiperidinyl Ether Derivatives as Amyloid-beta Aggregation Inhibitors

베타아밀로이드응집 억제제 도출을 위한 새로운 벤질피페리디닐에터 유도체의 합성

  • Published : 2006.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

We designed and synthesized new benzylpiperidinyl ether derivatives as beta-amyloid aggregation inhibitors for the development of novel anti-Alzheimer's disease agents. As starting material, 4-hydroxypiperidine was used. For protection of the amine group in piperidine (2), di-tert-butyl dicarbonate was reacted with 4-hydroxypiperidine in the presence of triethylamine. For introduction of benzyl group, benzylbromide was treated with compound 2 in dioxane. After deprotection of Boc group on amine in compound 3, ester (5) was synthesized by addition of ethyl-4-chlorobutyrate. The alcohol 6 was synthesized by hydride reduction of 5 using $LiAlH_4$. To obtain final products (7-14), the alcohol 6 was condensed with each of substituted benzoic acids. To screen beta-amyloid aggregation inhibition of the products, thioflavinT assay was performed using $A{\beta}1-42\;at\;37^{\circ}C$ for 26 h incubation, in vitro. From the result of screening, compound 8, 9, 11 and 12 showed effective activity about $65{\sim}85\;{\mu}M\;as\;IC_{50}$ value. Among the prepared compounds, 4-[4-(benzyloxy)piperidino]butyl-4-chlorobenzoate (8) was the most effective inhibitor having $IC_{50}\;of\;65.4{\mu}M$.

Keywords

References

  1. Khachaturian, Z. S. : Diagnosis of Alzhemier's disease. Arch. Neurol. 42, 1097 (1985) https://doi.org/10.1001/archneur.1985.04060100083029
  2. Selkoe, D. J. : Translating cell biology into therapeutic advances in Alzhemier's disease. Nature 399, A23 (1999) https://doi.org/10.1038/19866
  3. Hollander, E., Mohs, R. C. and Davis, K. L. : Cholinergic approaches to the treatment of Alzheimer's disease. Br. Med. Bull. 142, 97 (1986)
  4. Pietrzik, C. and Behl, C. : Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. Int. J. Exp. Pathol. 86, 173 (2005) https://doi.org/10.1111/j.0959-9673.2005.00435.x
  5. Silverberg, G. D., Mayo, M., Saul, T., Carvalho, J. and McGuire, D. : Novel ventriculo-peritoneal shunt in Alzheimer's disease cerebrospinal fluid biomarkers. Expert. Rev. Neurother. 4, 97 (2004) https://doi.org/10.1586/14737175.4.1.97
  6. Cottingham, M. G., Voskuil, J. L. and Vaux, D. J. : The intact human acetylcholinesterase C-terminal oligomerization domain is alpha-helical in situ and in isolation, but a shorter fragment forms beta-sheet-rich amyloid fibrils and protofibrillar oligomers. Biochemistry 42, 10863 (2003) https://doi.org/10.1021/bi034768i
  7. Prous, J., Rabasseda, X. and Castaner, J. : SDZ-ENA-713 cognition enhancer acetylcholinesterase inhibitor. Drugs Future 19, 656 (1996)
  8. Lilienfeld, S. : Galantamine - a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 8, 159 (2002) https://doi.org/10.1111/j.1527-3458.2002.tb00221.x
  9. Cottingham, M. G., Hollinshead, M. S. and Vaux, D. J. : Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide. Biochemistry 41, 13539 (2002) https://doi.org/10.1021/bi0260334
  10. De Ferrari, G. V., Canales, M. A., Shin, I., Weiner, L. M., Silman, I. and Inestrosa, N. C. : A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry 40, 10447 (2001) https://doi.org/10.1021/bi0101392
  11. Kurz, A. : The therapeutic potential of tacrine. J. Neural Transm. Suppl. 54, 295 (1998)
  12. Sugimoto, H. : Donepezil hydrochloride: a treatment drug for Alzheimer's disease. Chem. Rec. 1, 63 (2001) https://doi.org/10.1002/1528-0691(2001)1:1<63::AID-TCR9>3.0.CO;2-J
  13. Jann, M. W. : Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 20, 1 (2000) https://doi.org/10.1592/phco.20.1.1.34664
  14. Zarotsky, V., Sramek, J. J. and Cutler, N. R. : Galantamine hydrobromide: an agent for Alzheimer's disease. Am. J. Health Syst. Pharm. 60, 446 (2003)
  15. Barril, X., Orozco, M. and Luque, F. J. : Towards improved acetylcholinesterase inhibitors: a structural and computational approach. Mini. Rev. Med. Chem. 1, 255 (2001) https://doi.org/10.2174/1389557013406828
  16. Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A. and Klein, W. L. : Alzheimer's disease-affected brain: presence of oligomeric A-beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA 100, 10417 (2003)
  17. Petkova, A. T., Ishii, Y., Balbach, J. J., Antzutkin, O. N., Leapman, R. D., Delaglio, F. and Tycko, R. : A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints fromsolid state NMR. Proc. Natl. Acad. Sci. USA 99, 16742 (2002)
  18. Luhrs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Dobeli, H., Schubert, D. and Riek, R. : 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc. Natl. Acad. Sci. USA 102, 17342 (2005)
  19. Massi, F. and Straub, J. E. : Structural and dynamical analysis of the hydration of the Alzheimer's beta-amyloid peptide. J. Comput. Chem. 24, 143 (2003) https://doi.org/10.1002/jcc.10101
  20. Santini, S., Mousseau, N. and Derreumaux, P. : In silico assembly of Alzheimer's Abeta16-22 peptide into beta-sheets. J. Am. Chem. Soc. 126, 11509 (2004) https://doi.org/10.1021/ja047286i
  21. Greig, N. H., Sambamurti, K., Yu, Q. S., Brossi, A., Bruinsma, G. B. and Lahiri, D. K. : An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr. Alzheimer Res. 2, 281 (2005) https://doi.org/10.2174/1567205054367829
  22. Clarimon, J., Bertranpetit, J., Calafell, F., Boada, M., Tarraga, L. and Comas, D. : Association study between Alzheimer's disease and genes involved in Abeta biosynthesis, aggregation and degradation: suggestive results with BACE1. J. Neurol. 250, 956 (2003) https://doi.org/10.1007/s00415-003-1127-8
  23. Patrice, T. : $\beta$-Amyloid aggregation inhibitors for Treatment of Alzheimer's disease: Dream or Reality- Mini Reviews in Medicinal Chemistry 1, 175 (2001) https://doi.org/10.2174/1389557013407098